SCHEMBL9974704

SCHEMBL9974704

COC(=O)c1ccc(C)c(-c2ccc3c(=O)n(Cc4ccc(N5CCN(C)CC5)cc4)ccc3c2)c1

nearest known ligand 0.46

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
MAPK14 Q16539 3/20 0.46
MAPT P10636 2/20 0.43
KMT2A Q03164 2/20 0.42
CHKA P35790 1/20 0.41
LMNA P02545 2/20 0.41
DDR2 Q16832 2/20 0.41
LCK P06239 2/20 0.41
CSF1R P07333 2/20 0.41
EGFR P00533 2/20 0.41
KDR P35968 1/20 0.41
ERBB4 Q15303 1/20 0.41
FGFR1 P11362 1/20 0.40
ABL1 P00519 1/20 0.40
MEN1 O00255 1/20 0.39
TP53 P04637 1/20 0.38
ALDH1A1 P00352 1/20 0.38
NPC1 O15118 1/20 0.38
RAB9A P51151 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2419066 0.91 MAPK14 (0.48) MAPK14MAPTKMT2ALMNADDR2
SCHEMBL2415763 0.87 MAPK14 (0.64) MAPK14LCKCSF1RKDR
SCHEMBL9974723 0.85 LMNA (0.41) KMT2ALMNAMEN1ALDH1A1
SCHEMBL9974724 0.85 HDAC8 (0.47) MAPTLMNATP53ALDH1A1
SCHEMBL12284336 0.85 MAPK8 (0.43) KMT2ALMNAMEN1ALDH1A1
SCHEMBL9974659 0.85 P2RX7 (0.47) LMNAALDH1A1
SCHEMBL9974663 0.83 PTGS2 (0.45) KMT2ALMNAMEN1ALDH1A1NPC1
SCHEMBL2419000 0.81 LMNA (0.39) MAPTKMT2ALMNAMEN1TP53
SCHEMBL2422151 0.81 MAPK14 (0.51) MAPK14LCKCSF1RKDR
SCHEMBL2421106 0.79 MAPK14 (0.53) MAPK14DDR2LCKCSF1REGFR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2144881-B1 ISOQUINOLINONE DERIVATIVES, PROCESSES FOR THEIR PREPARATION AND THEIR USE IN THE TREATMENT OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE ( COPD ) AND ASTHMA ASTRAZENECA AB (SE) 2012-06-20 EP disclosed
US-8012979-B2 Compounds and their uses 707 ASTRAZENECA AB (SE) 2011-09-06 US disclosed
US-8012979-B2 Compounds and their uses 707 ASTRAZENECA AB (SE) 2011-09-06 US disclosed
US-20090023746-A1 COMPOUNDS AND THEIR USES 707 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
US-20090023746-A1 COMPOUNDS AND THEIR USES 707 ASTRAZENECA AB (SE) 2009-01-22 US disclosed
WO-2008122765-A1 NEW COMPOUNDS AND THEIR USES 707 ASTRAZENECA AB (SE) 2008-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090023746-A1 COMPOUNDS AND THEIR USES 707 CYP3A7, UGT1A7, UGT2B7 MAPK14 4537/4885MAPT 1419/4885KMT2A 3620/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.